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Tetrathiomolybdate-associated copper depletion
decreases circulating endothelial progenitor cells in
women with breast cancer at high risk of relapse
S. Jain, J. Cohen, M. M. Ward, N. Kornhauser, E. Chuang, T. Cigler, A. Moore,
D. Donovan, C. Lam, M. V. Cobham, S. Schneider, S. M. Hurtado Rúa, S. Benkert,
C. Mathijsen Greenwood, R. Zelkowitz, J. D. Warren, M. E. Lane, V. Mittal, S. Raﬁi
& L. T. Vahdat
Background: Bone marrow-derived endothelial progenitor cells (EPCs) are critical for metastatic progression. This
study explores the effect of tetrathiomolybdate (TM), an anti-angiogenic copper chelator, on EPCs in patients at high
risk for breast cancer recurrence.
Patients and methods: This phase 2 study enrolled breast cancer patients with stage 3 and stage 4 without
evidence of disease (NED), and stage 2 if triple-negative. TM 100 mg orally was administered to maintain ceruloplasmin
<17 mg/dl for 2 years or until relapse. The primary end point was change in EPCs.
Results: Forty patients (28 stage 2/3, 12 stage 4 NED) were enrolled. Seventy-ﬁve percent patients achieved the
copper depletion target by 1 month. Ninety-one percent of triple-negative patients copper-depleted compared with
41% luminal subtypes. In copper-depleted patients only, there was a signiﬁcant reduction in EPCs/ml by 27 (P = 0.04).
Six patients relapsed while on study, of which only one patient had EPCs maintained below baseline. The 10-month
relapse-free survival was 85.0% (95% CI 74.6%–96.8%). Only grade 3/4 toxicity was hematologic: neutropenia (3.1%
of cycles), febrile neutropenia (0.2%), and anemia (0.2%).
Conclusions: TM is safe and appears to maintain EPCs below baseline in copper-depleted patients. TM may
promote tumor dormancy and ultimately prevent relapse.
introduction
Despite improvements in adjuvant therapy of breast cancer
over the past two decades, there is signiﬁcant risk of relapse in
a high risk subset of patients. Although the deﬁnition of high
risk has been evolving, it still includes patients with stage 3
breast cancer and those with stage 4 with no evidence of
disease (NED). The risk of relapse in stage 3 patients is 50%
75% over 5 years, and patients with stage 4 breast cancer will
inevitably recur even when temporarily rendered disease free
by surgery, radiation, or chemotherapy [1]. Reﬂecting the
increasing importance of biology over stage, now included in
the deﬁnition is the triple negative subset [lack of expression of
estrogen receptor (ER)/progesterone receptor (PR), nor
overexpression of human epidermal growth factor 2 (HER2)].
These patients have a poor prognosis in earlier stages and
represent a disproportionately increased percentage with
metastatic disease [2 4].
The tumor microenvironment and its components,
including stromal ﬁbroblasts and endothelial and inﬂammatory
cells, play a major role in the establishment, progression, and
metastatic dissemination of cancer [5 11]. Using preclinical
models of breast cancer that metastasize to the lungs, the
premetastatic niche is comprised of recruited bone marrow
derived cells, including endothelial progenitor cells (EPCs;
CD45dim, CD133+, VEGFR2+), that modulate the angiogenic
switch for the progression of avascularized micrometastases to
vascularized macrometastases. VEGFR1+ hematopoietic
progenitor cells (HPCs) and CD11b+ myeloid progenitor cells
establish the premetastatic niche and recruit EPCs, among
other cells, to activate this angiogenic switch [12, 13]. EPC
deﬁciency results in impaired macrometastatic formation as a
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receptor CXCR4, involved in angiogenesis and metastatic 
progression, may have a role in EPC recruitment [36, 37]. In 
breast cancer patients, expression of SDF1 has been inversely 
correlated with survival [38]. In our study, SDF1 decreased 
with copper depletion but increased before relapse. Likewise, 
MMPs increased in patients before relapse. MMPs regulate 
tumor growth and invasion [36] and provide a permissive bone 
marrow niche to facilitate mobilization of progenitor cells [39]. 
Our observations suggest that SDF1 and MMPs may have 
important roles in metastatic progression.
Though a randomized clinical trial is necessary to assess 
survival, efﬁcacy measures were promising. Of 11 triple negative 
patients on study, only 2 relapsed. One patient did not 
adequately copper deplete despite incremental dose increases. 
The other patient progressed within 2 months of TM therapy, 
suggesting that active neoangiogenesis was occurring at the time 
of enrollment, which could not be halted due to delayed effects 
of copper depletion. We are cautiously optimistic about the low 
incidence of relapse and have extended the study to 6 years in 
selected patients. Two stage 4 NED triple negative patients 
remain disease free at 65 and 49 months on TM therapy, which 
is encouraging given the dismal median survival of 9 months in 
metastatic triple negative patients [2].
In summary, we have conducted the ﬁrst phase II study 
employing copper chelation in high risk breast cancer patients 
with minimal residual disease. As the evidence accumulates in 
favor of copper depletion to prevent relapse, a large, 
randomized, multicenter trial enriched with triple negative and 
stage 4 NED patients may be of utility.
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